{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 352, "pageCount": 415, "prevPage": 351, "nextPage": 353, "slideType": "testimonial", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/352", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-352", "components": [ { "bbox": null, "kind": "callout", "text": "“Cynical” and has “hesitancy” about Vykat due to known dangers of diazoxide; “problems with the study trial design”; small size of trial; “have to be cautious”", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2b4-8b44536260ce", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "paragraph", "text": "Indicated he has no plans to prescribe Vykat, stating that diazoxide is an old drug with a severe toxicity profile that it well-known to endocrinologists; trashed Soleno’s clinical trials – “this is going to sound maybe cynical, but I’m overall…I’m skeptical in terms of if it’s going to be successful or not”; “how much benefit are we going to get from this? Number two, I’m aware of what diazoxide is…so, it’s kind of like, hmm…diazoxide can be problematic for other reasons…you have to be cautious about it because there can be some not very good side effects”; “problems with the study trial design itself, the power of the study, how much statistical significance is going to be there? It’s all rather difficult to say. That’s the reason for my hesitancy.”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7d08c97c-3bb6-42ea-b54c-964688f50d23", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.65 }, "kind": "paragraph", "text": "“Cynical” and has “hesitancy” about Vykat due to known dangers of diazoxide; “problems with the study trial design”; small size of trial; “have to be cautious”\n“I would say that I know this is going to sound maybe cynical, but I’m overall, when it comes to rare diseases like this, I would say I’m skeptical in terms of if it’s going to be successful or not, because number one, these are very rare diseases. How much benefit are we going to get from this? Number two, I’m aware of what diazoxide is. So, it’s kind of like, hmm. Diazoxide can be problematic for other reasons. I would say you have to be cautious about it because there can be some not very good side effects. And since it’s such a rare disease, I don’t know what good of a power these clinical trials are going to have because they’re going to have a low amount of patients since it’s a rare disease. There’s going to be problems with the study trial design itself, the power of the study, how much statistical significance is going to be there? It’s all rather difficult to say. That’s the reason for my hesitancy.” - Endocrinologist at Massachusetts General Hospital", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "83e7b99a-271b-4eff-b780-0faaf9f8e1e8", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.86, "x": 0.07, "y": 0.52 }, "kind": "paragraph", "text": "Endocrinologist at Massachusetts General with 5 PWS patients\n“I’m actually an adult endocrinologist. I have maybe up to five PWS. They’re in early adulthood. I have a very rather small amount, as you know, PWS is a rare disease. But I know some things about it. I’m an adult endocrinologist.” - Endocrinologist at Massachusetts General Hospital", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d9eccf2c-400b-4c94-bb8f-7d781d3f6ae1", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“I would say that I know this is going to sound maybe cynical, but I'm overall, when it comes to rare diseases like this, I would say I'm skeptical in terms of if it's going to be successful or not, because number one, these are very rare diseases. How much benefit are we going to get from this? Number two, I'm aware of what diazoxide is. So, it's kind of like, hmm. Diazoxide can be problematic for other reasons. I would say you have to be cautious about it because there can be some not very good side effects. And since it's such a rare disease, I don't know what good of a power these clinical trials are going to have because they're going to have a low amount of patients since it's a rare disease. There's going to be problems with the study trial design itself, the power of the study, how much statistical significance is going to be there? It's all rather difficult to say. That's the reason for my hesitancy.” — Endocrinologist at Massachusetts General Hospital", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2b4-8feaf507e181", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3b7fcda2-8567-410b-8c16-3e28f18aab18", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "PWS endocrinologist #3: Specialist at Massachusetts General Hospital with ~5 Prader-Willi patients.", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "02ba5502-92b0-42f2-85f5-607a098f9d90", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }